Yes, Mr. Chair.
The important thing for me is to adopt the motion today. In terms of how we proceed, I'm open to ideas.
In any case, the various interest groups are already prepared, since they've already submitted briefs. The important thing today is to give people the opportunity to speak. I should point out that the consultations were conducted in writing and in a very closed manner. Some people want to speak, and I think that we must hear from them as soon as possible.
Of course, I'd like us to hear from all the people who want to meet with us. There aren't that many people. They're all part of groups, such as patient associations, industry groups, or research and life sciences groups. There are also economists who are a little more neutral. These economists are currently having a very difficult time measuring the real impact of these guidelines, not only on the introductory ceiling price of drugs, but also on patients' access to innovative therapies over the coming years, particularly in immunology and oncology. Trikafta is a good example of this.
In short, I want us to move forward. We'll be able to hold discussions and make adjustments as we discover things. I gather today that everyone has agreed to move forward. Based on what I'm hearing from both sides, I'm confident that we'll work well together on this study. I'm very optimistic.